ROCKVILLE, Md., May 8, 2019 /PRNewswire/ -- REGENXBIO Inc.
(Nasdaq: RGNX), a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy based on its proprietary NAV® Technology
Platform, today announced it will present at the Bank of America
Merrill Lynch 2019 Healthcare Conference on Wednesday, May 15, 2019, at the Encore Wynn
Hotel, Las Vegas, NV:
Fireside chat: Wednesday, May 15, 2019, at
10:40 a.m. PDT (1:40 p.m. EDT)
Gene Therapy Panel: Wednesday, May 15, 2019, at
4:20 p.m. PDT (7:20 p.m. EDT)
A live webcast of the fireside chat can be accessed in the
Investors section of REGENXBIO's website at www.regenxbio.com. An
archived replay of the fireside chat webcast will be available on
the same website for approximately 30 days following the
presentation.
About REGENXBIO
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV® Technology Platform, a
proprietary adeno-associated virus (AAV) gene delivery platform,
consists of exclusive rights to more than 100 novel AAV vectors,
including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its
third-party NAV Technology Platform Licensees are applying the NAV
Technology Platform in the development of a broad pipeline of
candidates in multiple therapeutic areas.
CONTACT:
Investors
Heather
Savelle, 212-600-1902
heather@argotpartners.com
Media
David Rosen,
212-600-1902
david.rosen@argotpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/regenxbio-to-present-at-the-bank-of-america-merrill-lynch-2019-healthcare-conference-300845832.html
SOURCE REGENXBIO Inc.